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PCardiac Rhythm Disturbances
Randomized, Controlled Trial of
SD1235, a Novel Anti-Arrhythmic Agent,
n the Treatment of Recent Onset Atrial Fibrillation
enis Roy, MD, FACC,* Brian H. Rowe, MD, MSC,† Ian G. Stiell, MD, MSC,‡ Benoit Coutu, MD,§
ohn H. Ip, MD, Denis Phaneuf, MD,¶ Jacques Lee, MD, MSC,# Humberto Vidaillet, MD, FACC,**
arth Dickinson, MD,‡ Sheila Grant, MBA,†† Alan M. Ezrin, PHD,†† Gregory N. Beatch, PHD,††
or the CRAFT Investigators
ontreal, Edmonton, Ottawa, Toronto, and Vancouver, Canada; Lansing, Michigan; and Marshfield, Wisconsin
OBJECTIVES The purpose of this study was to determine the efficacy and safety of intravenous RSD1235
in terminating recent onset atrial fibrillation (AF).
BACKGROUND Anti-arrhythmic drugs currently available to terminate AF have limited efficacy and safety.
RSD1235 is a novel atrial selective anti-arrhythmic drug.
METHODS This was a phase II, multi-centered, randomized, double-blinded, step-dose, placebo-
controlled, parallel group study. Fifty-six patients from 15 U.S. and Canadian sites with AF
of 3 to 72 h duration were randomized to one of two RSD1235 dose groups or to placebo.
The two RSD1235 groups were RSD-1 (0.5 mg/kg followed by 1 mg/kg) or RSD-2
(2 mg/kg followed by 3 mg/kg), by intravenous infusion over 10 min; a second dose was given
only if AF was present. The primary end point was termination of AF during infusion or
within 30-min after the last infusion. Secondary end points included the number of patients
in sinus rhythm at 0.5, 1, and 24 h post-last infusion and time to conversion to sinus rhythm.
RESULTS The RSD-2 dose showed significant differences over placebo in: 1) termination of AF (61%
vs. 5%, p  0.0005); 2) patients in sinus rhythm at 30 min (56% vs. 5%, p  0.001); 3) sinus
rhythm at 1 h (53% vs. 5%, p  0.0014); and 4) median time to conversion to SR (14 vs. 162
min, p  0.016). There were no serious adverse events related to RSD1235.
CONCLUSIONS RSD1235, a new atrial-selective anti-arrhythmic agent, appears to be efficacious and safe for
converting recent onset AF to sinus rhythm. (J Am Coll Cardiol 2004;44:2355–61) © 2004
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.021by the American College of Cardiology Foundation
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strial fibrillation (AF) is the most common sustained
rrhythmia, and its development or exacerbation often
rompts emergency department presentations. Conversion
f AF to sinus rhythm is often attempted in the acute
etting to improve symptoms and to prevent the detrimental
emodynamic effects that AF may have in some patients
e.g., valvular disease or left ventricular dysfunction). Early
onversion of AF may also prevent the development of
lectrical remodeling (1) and the embolic risks associated
ith intra-atrial thrombus formation (2). Electrical cardio-
ersion is effective in restoring sinus rhythm but requires
rocedural sedation or anesthesia and is not successful in all
ases. Currently available converting agents have highly
ariable efficacy and several safety limitations associated
ith their use (3–21). In addition, placebo-controlled trials
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ia, Canada. This study was sponsored by Cardiome Pharma.c
Manuscript received April 30, 2004; revised manuscript received August 19, 2004,
ccepted September 3, 2004.hat establish the efficacy and safety of these pharmacologic
herapies for acute conversion are limited. An efficacious,
imple, and safe pharmacologic alternative to existing meth-
ds of cardioversion would be a welcome development for
atients with AF and their treating physicians.
RSD1235, a novel compound, was developed by Cardi-
me Pharma (Vancouver, British Columbia, Canada) and is
mixed frequency-dependent Na and atria-preferential
 channel blocker. In animal models of AF, RSD1235 is
ffective in terminating and preventing relapse of AF. In
everal preclinical studies, RSD1235 has been shown to
electively prolong atrial refractory periods without signifi-
ant effects on ventricular refractoriness or QT intervals
22,23). The drug has been demonstrated to be safe in a
ariety of doses in healthy volunteers (24). The present
linical study was designed to examine the efficacy and safety
f intravenous RSD1235 using a step-dosing design for
apid termination of AF.
ETHODS
esign. The study protocol was approved by the institu-
ional or ethics review boards at each of the participating
ites. This was a prospective double-blinded, placebo-
ontrolled, randomized, dose-response trial. Multiple levels
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RSD1235 for Conversion of Atrial Fibrillation December 21, 2004:2355–61f blinding were employed, including the treating physician,
atient, treating nurse, research nurse, family physician,
ollow-up assessment, and outcome adjudicators.
nclusion criteria. To be eligible, patients with recent onset
F (recurrent or new onset) had to have AF with a continuous
uration of 3 to 72 h at the time of randomization. Patients
ere managed in accordance with American College of Car-
iology/American Heart Association/European Society of
ardiology anticoagulation practice guidelines (25). Patients
21 years of age were eligible. All patients had to be hemo-
ynamically stable (systolic blood pressure 90 to 160 mm Hg;
iastolic blood pressure 95 mm Hg) and provide written,
nformed consent.
xclusion criteria. Exclusion criteria included female pa-
ients of child-bearing potential; weight136 kg; history of
ong QT syndrome, torsade de pointes, or an uncorrected
T interval of 450 ms; QRS 120 ms; myocardial in-
arction; symptoms of angina; congestive heart failure;
troke within the previous three months; cardiac surgery in
he previous six months; bradycardia (50 beats/min) or
ick sinus syndrome, unless controlled by a pacemaker;
igoxin toxicity; reversible cause of AF (such as hyperthy-
oidism, pulmonary embolism, alcohol intoxication, acute
ericarditis); Wolff-Parkinson-White syndrome; chronic
bstructive pulmonary disease requiring daily bronchodila-
ion therapy; cyanotic or other significant congenital heart
isease; concurrent treatment with known QT-prolonging
rugs or class I or III anti-arrhythmic agents (unless the
edication was discontinued more than five half-lives
efore enrollment); oral amiodarone in the prior six months
r intravenous amiodarone in the previous month; end-
tage disease; and the following laboratory abnormalities:
erum potassium 3.5 mEq/l, magnesium 1.5 mEq/l,
erum creatinine 1.8 mg/dl, hemoglobin 9 g/dl in
omen or11 g/dl in men, and liver enzymes 1.5 times the
aximal normal values. No alcohol, caffeine, herbal reme-
ies, or smoking was permitted during the study. Pre-
nrollment treatment with beta-adrenergic blocking agents,
alcium antagonists, and digoxin for control of ventricular
ate was permitted.
reatments. Patients were randomized to one of three
roups and in each group received up to two 10-min intrave-
ous infusions, separated by 30 min. Infusions were placebo
ollowed by placebo, 0.5 mg/kg followed by 1.0 mg/kg
SD1235 if required, or 2.0 mg/kg followed by 3.0 mg/kg
SD1235 if required. The second dose in each group was
dministered only if AF was present 30 min after completion
f the first dose. Doses for patients weighing 113 kg were
Abbreviations and Acronyms
AF  atrial fibrillation
ECG  electrocardiogram/electrocardiographicapped as if the patient’s weight was 113 kg. butcomes. Efficacy outcomes were adjudicated by Drs.
ickinson, Rowe, and Ezrin before unblinding of treatment
llocation; disagreements were resolved following a second
eview and consensus. The primary efficacy end point of this
tudy was the termination of AF (which could include
onversion of AF to sinus rhythm or another atrial rhythm,
uch as atrial flutter) for any length of time during infusion
r within 30 min after the end of the last infusion. As such,
atients whose AF terminated during or within 30 min after
he end of the first infusion met the primary end point, as
ell as those patients requiring a second infusion, whose AF
erminated during or within 30 min after the end of their
econd infusion. Secondary end points included the number
f patients in sinus rhythm at 0.5, 1, and 24 h after the end
f their last infusion, as well as the time to conversion to
inus rhythm from first exposure to study drug.
rotocol. A Holter rhythm strip continuously monitored
he electrocardiogram (ECG); vital signs (blood pressure
nd heart rate) and oxygen saturation were recorded every
min from the start of infusion to 5 min after, as well as at
5, 30, 60, 120, 240, 360, and 480 min and at discharge and
ne-week follow-up. Twelve-lead ECGs were obtained
efore dosing and every minute during infusion to 5 min
fter, as well as at 15, 30, 60, 120, 240, 360, and 480 min,
ischarge, 24-h and 1-week follow-up, and the time of
rrhythmia termination or significant rhythm changes. The
CGs were interpreted by individual investigators and
ndependently verified by a core laboratory cardiologist
linded to study treatment. Venous blood samples were
rawn for RSD1235 plasma concentrations at 0, 15, 30,
20, 240, and 480 min, discharge, and AF termination or
ignificant adverse events. The infusion was discontinued if
he arrhythmia terminated after 1 min of verification,
ystolic blood pressure decreased to 85 mm Hg or
ncreased to 190 mm Hg, HR was 50 beats/min,
ntolerable side effects or any change in rhythm or atrioven-
ricular conduction occurred that in the investigator’s opin-
on was a threat to patient safety, a new bundle-branch
lock developed, the QRS complex increased 50%, the
ncorrected QT interval increased to 550 ms or 25% of
aseline, or any polymorphic ventricular tachycardia was
oted. If AF persisted past 1 h after the end of the last
nfusion received, electrical cardioversion was permitted.
he use of other anti-arrhythmic agents was discouraged
ntil 12 h after the RSD1235 infusion, unless the investi-
ator considered it necessary to restore sinus rhythm earlier.
tatistical considerations. The sample size was based on
stimates of a placebo conversion rate of 35%, RSD1235
onversion rate of 60%, an alpha value of 0.05, and a beta
alue of 0.9.
All patients who received any amount of study medi-
ation (n  56) were included in the safety and efficacy
nalysis. Subjects who where randomized but did not
eceive study medication were not included in the anal-
sis. Under the principles of randomization and double-
linded treatments, and given that the decision to exclude
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December 21, 2004:2355–61 RSD1235 for Conversion of Atrial Fibrillationhese patients was not based on knowledge of the
reatment to be received, the remaining patients con-
ormed to the intention-to-treat philosophy and provide
n unbiased comparison of the true effect of RSD1235 in
he termination of AF. Furthermore, as no study medi-
ation was administered to the excluded patients, it
ould have been impossible to determine efficacy accord-
ng to the primary or secondary end points (AF termi-
ation relative to infusion time). Data are presented as
he mean value  SD or median value with interquartile
ange. All tests were performed as two-sided, and the 95%
onfidence interval was produced; p  0.05 was considered
tatistically significant, unless stated otherwise. Analysis of
he relationship between termination of AF and treatment
as performed using chi-square analysis. In cases of small
ell frequencies, the Fisher exact test was used. A Cochran-
rmitage test statistic with table scores was used to test the
scending dose evaluation of efficacy.
Patients who were electrically cardioverted were not
valuated for secondary end points. The time to conver-
ion from the start of the first infusion was analyzed by
he Cox regression method of event time analysis and
ne-way analysis of variance. Assessment of the signifi-
ance of time point values and the mean change from
aseline to each follow-up reading of ECG intervals
QRS, QT, corrected QT), blood pressures, and heart
ates were made within dose groups using the paired t
est, and comparisons among dose groups were made
sing one-way analysis of variance.
ESULTS
atient recruitment. Sixty-five eligible patients provided
onsent to enter the study and were randomized from 15
articipating centers between January 16, 2002, and July 5,
002. Nine patients were randomized but did not receive
Table 1. Demographic Characteristics for Pati
Placebo
(n  20)
Male gender 14 (70%)
Age (years) 64.0 (35–83)
Duration of AF (h) 13.3 (5.1–59
Previous AF history 75%
Lone AF 35%
Hypertension 45%
Diabetes 25%
Concomitant beta1-blocker 75%
Concomitant ACE inhibitor 30%
Concomitant diltiazem/verapamil 30%
Concomitant digitalis 30%
This table shows the baseline demographics of the patien
differences in baseline characteristics between the groups, som
fibrillation (AF) episode tended to be longer in the RSD-2 tr
have presented with recurrent AF in the placebo group. Abou
disease). A high percentage of patients were taking concomit
as the number (%) of patients, median value (range), or perc
ACE  angiotensin-converting enzyme.he study drug (seven not remaining in AF at the time of gntended study drug administration; one with screening
ailure; and one who withdrew consent), and they were
ithdrawn from further participation in the study. One
atient received the study drug (placebo) and was included
n the efficacy analysis per the intention-to-treat principle,
lthough he failed to meet the AF duration entry criteria.
he treatment allocation was as follows: placebo/placebo
n  20); 0.5 mg/kg  1.0 mg/kg RSD1235 (n  18); and
.0 mg/kg  3.0 mg RSD1235 (n  18).
atient characteristics (Table 1). There were no statistical
ifferences in the baseline characteristics of the three patient
roups. Patients in the placebo group tended to report AF
ore frequently in the past than did those in the RSD1235-
osed groups.
rimary end point. The cumulative AF termination within
0 min after the last infusion was 61% (11 of 18 patients)
fter 2  3 mg/kg RSD1235 infusion, 11% (2 of 18
atients) after 0.5  1 mg/kg RSD1235, and 5% (1 of 20
atients) after placebo  placebo (Fig. 1). Paired compar-
sons indicated a statistically significant difference (p 
.0005) between placebo and the RSD-2 groups. There was
o significant difference in the success rates between the
SD-1 and placebo groups. Of the 11 AF terminations in
he RSD-2 group, 10 converted to sinus rhythm and 1
onverted into atrial flutter.
The median time to termination of AF was 11 min after
he start of the first infusion (range 3 to 58 min) in the
SD-2 group. In fact, all the responders in this group
eached the primary end point during drug infusion or
ithin 10 min of the last infusion. The patient in the
SD-2 group who converted from AF into atrial flutter
ubsequently converted to sinus rhythm 14.5 h later.
econdary end points. The percentage of patients in sinus
hythm (excluding those electrically cardioverted) at 30 min
fter infusion was 56% (10 of 18 patients) in the RSD-2
n Each Study Group
RSD1235
(0.5 and 1.0 mg/kg)
(n  18)
RSD1235
(2.0 and 3.0 mg/kg)
(n  18)
10 (56%) 10 (56%)
67.4 (24–85) 60.8 (25–88)
11.5 (5.7–67.2) 19.5 (5.1–70.4)
61% 44%
28% 39%
72% 56%
28% 17%
61% 67%
28% 22%
22% 33%
22% 11%
omized in the study. Although there were no significant
t differences were noted. The duration of the qualifying atrial
nt group, whereas there was a tendency for more patients to
hird of patients had lone AF (absence of other cardiovascular
e-control medications across the groups. Data are presented
of patients.ents i
.4)
ts rand
e sligh
eatme
t one-t
ant ratroup, 11% (2 of 18 patients) in the RSD-1 group, and 5%
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RSD1235 for Conversion of Atrial Fibrillation December 21, 2004:2355–611 of 20 patients) in the placebo group. The percentage of
atients in sinus rhythm at 1 h after infusion was 53% (9 of
7 patients) in the RSD-2 group, 11% (2 of 18 patients) in
he RSD-1 group, and 5% (1 of 20 patients) in the placebo
roup. The percentage of patients in sinus rhythm at 24 h
fter infusion was 79% (11 of 14 patients) in the RSD-2
roup, 56% (5 of 9 patients) in the RSD-1 group, and 45%
5 of 11 patients) in the placebo group. Only the difference
etween RSD-2 and placebo was statistically significant at
0 min (p  0.01) and at 1 h (p  0.005).
The median time to conversion to sinus rhythm during the
4-h observation period (excluding those electrically cardio-
erted) from the start of the first infusion in the RSD-2 group
n  11) was 14 min (range 3 to 871 min, p  0.016),
ompared with the placebo group (n 5), with a median time
f 162 min (range 58 to 1,119 min). The median time to
onversion to sinus rhythm in the RSD-1 group (n  5) was
66 min (range 1 to 332 min, p  0.886 vs. placebo).
lectrocardiographic effects of RSD1235. The RSD1235
nfusion did not significantly prolong the QTc or QRS
ntervals, as compared with placebo (Table 2). There was no
ifference in the QT and QTc intervals between placebo (389
31 ms vs. 414  16 ms) and RSD-2 treatment (366  28
s vs. 427 19 ms) using the first available ECG records after
onversion to sinus rhythm.
emodynamic effects. There were no clinically significant
hanges from baseline in systolic blood pressure, and there
ere no changes in blood pressure that were substantially
ifferent from those seen in the placebo group. There were
wo significant cases of hypotension reported in the placebo
roup and one mild case of transient hypotension in the
SD-2 group. Clinically significant treatment-related de-
igure 1. Cumulative percentage of patients terminating atrial fibrillatio
.0 mg/kg RSD1235 in patients with recent onset AF. Efficacy was sign
nd was significantly different between the two RSD1235 (p  0.002)
he start of the first infusion in the RSD1235 treatment groups.reases in mean heart rate from baseline (mean 106 beats/ pin) occurred in patients administered the RSD-2 dose,
tarting at T1  15 min (mean 90 beats/min). This likely
eflected the conversion of several patients to normal sinus
hythm.
dverse events. A total of 39 patients experienced 122
dverse events over the course of the study, with a similar
ncidence of events among the three treatment groups. The
ajority of adverse events were of mild or moderate inten-
ity. There were four mild adverse events that occurred in
wo patients considered either definitely or probably related
o study drug. Both patients were in the RSD-2 dose group:
ne patient reported paresthesia, and one patient reported
aresthesia, nausea, and hypotension.
The most common adverse events experienced in this
tudy were cardiac disorders, reported by seven patients
35.0%) in the placebo group, four patients (22.2%) in the
SD-1 group, and three patients (16.7%) in the RSD-2
roup. In addition to the serious adverse events discussed
ubsequently, the cardiac disorders in the placebo group
ncluded two patients with nonsustained ventricular tachy-
ardia and a patient with ventricular premature beats.
entricular premature beats were also seen in two patients,
nd sinus bradycardia was found in one patient in the
ow-dose group. Ventricular premature beats were seen in
wo patients, and sinus bradycardia in another patient in the
SD-2 group. Other adverse events occurring with a similar
requency among treatment groups were nervous system
isorders, general disorders, and infections.
erious adverse events. Serious adverse events were re-
orted in five patients (four in the placebo group and one in
he RSD-1 group). A transient cerebral ischemic attack
ccurred one day after conversion in a placebo-treated
F) after infusions of placebo, 0.5 and 1.0 mg/kg RSD1235, or 2.0 and
tly higher after 2  3 mg/kg RSD1235 than after placebo (p  0.0003)
g regimens. The median time for termination of AF was 11 min fromn (A
ificanatient with a therapeutic international normalized ratio at
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December 21, 2004:2355–61 RSD1235 for Conversion of Atrial Fibrillationhe time of conversion. Severe bradycardia and hypotension
mmediately after conversion occurred in one patient, pul-
onary edema in another patient, and recurrent AF in the
ourth placebo patient. One patient in the RSD-1 group
xperienced ventricular fibrillation, which was attributed to
n asynchronous discharge during an electrical cardioversion
ttempt performed 1 h after receiving the second infusion.
Table 2. Corrected QT and QRS Intervals and
Study Group
Time Period Placebo (0.5
QTc (ms)
Predrug baseline (n) 20
Mean  SD 424 6
End infusion no. 1 (n) 19
Mean  SD 430 5
End infusion no. 2 (n) 16
Mean  SD 436 8
QRS (ms)
Predrug baseline (n) 20
Mean  SD 87  2
End infusion no. 1 (n) 19
Mean  SD 89  2
End infusion no. 2 (n) 16
Mean  SD 88  2
Heart rate (beats/min)
Predrug baseline (n) 20
Mean  SD 112 6
End infusion no. 1 (n) 19
Mean  SD 115 6
End infusion no. 2 (n) 16
Mean  SD 109 6
This table shows the baseline values and effects of infusion
groups. There were no statistically significant differences in e
rate was decreased after 2 mg/kg RSD1235 (p  0.05), reflec
group. Data are presented as the mean value  SD.
igure 2. Plasma concentrations of RSD1235 after infusion in patients do
t 3 mg/kg intravenously (circles). The RSD1235 doses were infused over 10 m
f required, an additional 3 mg/kg was infused 30 min later in the RSD-2 grouollow-up through 24 h. Within the study period (24 h),
lectrical cardioversion was attempted in 9 (45%) of 20
lacebo-treated, 9 (50%) of 18 RSD-1-treated, and 4 (22%)
f 18 RSD-2–treated patients, and it was successful in 8
89%), 9 (100%), and 4 (100%) patients, respectively.
harmacokinetic analysis. Mean peak RSD1235 plasma
evels were 5.8 g/ml (range 4.0 to 8.6 g/ml) in the
art Rate Values for Patients in Each
D1235
1.0 mg/kg)
RSD1235
(2.0 and 3.0 mg/kg) p Value
16 17
 6 434  7 0.233
17 17
 6 449  9 0.066
17 11
 11 447  17 0.691
17 18
 3 86  3 0.823
17 17
 3 95  3 0.150
17 11
 6 99  5 0.120
16 17
 6 108  6 0.585
17 17
 7 98  5 0.045
17 11
 6 104  6 0.601
c and QRS intervals as well as heart rate in the treatment
ardiographic intervals after infusion between groups. Heart
e number of patients who converted to sinus rhythm in this
2 mg/kg intravenously (inverted triangles) and those additionally dosedHe
RS
and
417
419
414
83
86
90
101
104
107
on QT
lectrocsed at
in, as indicated in the text. Initially, a 2-mg/kg infusion was given, and,
p. Time is shown relative to the end of the first infusion (T1).
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RSD1235 for Conversion of Atrial Fibrillation December 21, 2004:2355–61atients who received both the 2.0- and 3.0-mg/kg infu-
ions of RSD1235 (Fig. 2) and 1.9 g/ml (range 0.1 to 3.4
g/ml) in those who received both the 0.5- and 1.0-mg/kg
SD1235 infusions. Maximum plasma levels were seen at
he end of the second infusion. The lower limit of detection/
uantification of RSD1235 in plasma was 5 ng/ml. Plasma
evels of RSD1235 at 24 h were below this lower limit of
uantification in most patients who received RSD-1. Sim-
larly, negligible plasma levels were seen at 24 h in the
SD-2 group; mean plasma levels were 0.017 g/ml (range
0.005 to 0.028 g/ml). In those patients who received
nly the 2-mg/kg infusion, the mean peak plasma levels at
he end of infusion were 2.6 g/ml (range 1.4 to 4.5 g/ml).
he median plasma level at the time of AF conversion in
hese patients was 1.3 g/ml (range 1.1 to 3.5 g/ml). The
ean terminal elimination half-life in these patients was
.1 h (range 1.7 to 5.4 h).
ISCUSSION
his phase II dose-finding study demonstrated that the
pper dose of RSD1235 (2  3 mg/kg) rapidly and
ffectively terminated AF compared with lower dose
SD1235 and placebo. There were no serious adverse
vents associated with RSD1235. In contrast to other
nti-arrhythmic drugs used for conversion of recent onset
F, there were no instances of drug-related pro-arrhythmia.
lthough these initial findings will require confirmation in
arger scale clinical trials, this safety profile, coupled with an
fficacious and rapid onset, confirms that RSD1235 is a
romising new agent for the medical conversion of recent
nset AF.
Cardioversion of AF may be accomplished using electri-
al or pharmacologic approaches. Electrical cardioversion is
ffective in rapidly restoring sinus rhythm; however, it
equires procedural sedation and a suitable recovery period
nd/or may cause pain after treatment. Experimental data
uggest that AF itself conditions the substrate for mainte-
ance of AF and supports the need for early arrhythmia
ermination to prevent electrical remodeling (1). In this
egard, rapid intravenous conversion of AF should be
referable to oral anti-arrhythmic agents that may require
p to 24 h to act (3). We chose a very short follow-up time
fter infusion for primary efficacy analysis in order to
istinguish drug efficacy from placebo, as the placebo
esponse rate is relatively high in patients with AF of less
han three days’ duration. We also thought that responsive-
ess to drug within 30 min of infusion was a clinically
elevant end point, because it allows for rapid conversion of
F within an emergency department setting.
RSD1235 appears to shows a high clinical efficacy (56%)
or conversion of recent onset AF to sinus rhythm within
h of exposure and compares favorably to other intravenous
nti-arrhythmic agents reported in published data. For
xample, in recent onset AF, placebo-controlled studies of
ntravenous class IC agents (flecainide and propafenone)ave had efficacy rates (corrected for placebo response rate)
f 25% to 53% within 2 h of infusion (3). The efficacy of
ntravenous amiodarone is highly variable; however, it is
onsidered less than that with the class IC agents (15–18).
urthermore, responses that take 24 h to manifest, such as
ith amiodarone, are of limited usefulness for acute intra-
enous conversion of AF. Class III anti-arrhythmics, such
s ibutilide and dofetilide, show 20% to 30% net efficacy
ates for conversion of AF, with slightly higher efficacy in
ermination of atrial flutter (3,18,20,21). These latter agents
re associated, however, with a relatively high incidence of
rug-induced pro-arrhythmia (18,20). Intravenous sotalol,
nother agent with class III activity, has not been shown to
e effective in restoring sinus rhythm in patients with atrial
rrhythmias (19).
tudy limitations. First, this study had a small sample size,
nd these initial findings will require confirmation in ongo-
ng larger scale clinical trials. Second, the inclusion and
xclusion criteria were rigid, and future trials should include
ost-cardiac surgery patients and those concurrently receiv-
ng other anti-arrhythmic agents. Finally, there were no
uality-of-life assessments.
onclusions. Notwithstanding these concerns, this ran-
omized, controlled trial provides evidence for the efficacy
f this novel, atrial-selective, Na/K channel blocking
gent for the treatment of recent onset AF. Intravenous
SD1235 (2  3 mg/kg) was effective in rapidly terminat-
ng AF and was not associated with any drug-induced
ro-arrhythmia or any serious adverse event. RSD1235
ppears to be a potential alternative to existing chemical and
lectrical cardioversion for rapid termination of AF.
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